Eton Pharmaceuticals (ETON) Common Equity: 2019-2025
Historic Common Equity for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $23.1 million.
- Eton Pharmaceuticals' Common Equity rose 44.71% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 44.71%. This contributed to the annual value of $24.4 million for FY2024, which is 57.83% up from last year.
- As of Q3 2025, Eton Pharmaceuticals' Common Equity stood at $23.1 million, which was down 3.48% from $24.0 million recorded in Q2 2025.
- Eton Pharmaceuticals' Common Equity's 5-year high stood at $24.4 million during Q1 2025, with a 5-year trough of $11.2 million in Q3 2022.
- Moreover, its 3-year median value for Common Equity was $16.7 million (2023), whereas its average is $18.3 million.
- Per our database at Business Quant, Eton Pharmaceuticals' Common Equity skyrocketed by 1,028.24% in 2021 and then crashed by 37.91% in 2022.
- Eton Pharmaceuticals' Common Equity (Quarterly) stood at $17.6 million in 2021, then fell by 25.82% to $13.1 million in 2022, then increased by 18.34% to $15.5 million in 2023, then soared by 57.83% to $24.4 million in 2024, then surged by 44.71% to $23.1 million in 2025.
- Its Common Equity was $23.1 million in Q3 2025, compared to $24.0 million in Q2 2025 and $24.4 million in Q1 2025.